Preview

Rational Pharmacotherapy in Cardiology

Advanced search

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION

https://doi.org/10.20996/1819-6446-2012-8-1-23-30

Full Text:

Abstract

Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance in percutaneous coronary intervention (PCI), to identify clinical risk factors of resistance development, to study effects of concomitant therapy on resistance development, to identify relationship between risk of cardiovascular complications and activity of platelet aggregation, to assess safety of dual antiplatelet therapy , and to suggest possible ways to overcome clopidogrel resistance. Material and Methods. Patients (n=100) with stable angina class II-IV, that were planned for PCI, were included in the study. Patients randomized to group A (n=53) received clopidogrel 75 mg daily for 7 days before PCI, and later were allocated to subgroups of clopidogrel sensitive or resistant depending on platelet aggregation. In resistant subgroup clopidogrel daily dose was increased to 150 mg for the whole next period of observation. Patients randomized to group B (n=47) received a loading dose of clopidogrel 300 mg one day before PCI. Depending on the results of platelet reactivity assessment, patients were split into sensitive or resistant subgroups. Patients of resistant subgroup received the second loading dose of clopidogrel 300 mg before PCI and started to take clopidogrel 150 mg daily after PCI. Patients of sensitive subgroup did not receive the second clopidogrel loading dose and started to take clopidogrel in usual daily dose of 75 mg. The combined endpoint (after 6 and 12 months) included cardiovascular death, recurrent nonfatal myocardial infarction, recurrent angina, acute ischemic stroke, acute impairment of peripheral circulation. Results. Increased reactivity of platelets to acetylsalicylic acid was detected in 21% of patients. Resistance to clopidogrel in both groups was 56%. Double resistance was registered in 8% of patients. The development of resistance to clopidogrel was related with obesity (p=0.014) and hyperglycemia (p=0.017). 4 and 11 cardiovascular events were registered in 6 and 12 months, respectively. Conclusion. To assess efficacy of antiplatelet therapy it is advisable to study platelet aggregation before and shortly after PCI, especially in patients with obesity and glucose metabolism disturbances. Knowledge of changes in platelet aggregation during clopidogrel therapy can be usefull for timely correction of antiplatelet therapy. Increase in clopidogrel dose up to 150 mg a day is one of the possible way to overcome resistance to clopidogrel.

About the Authors

V. A. Sulimov
I.M. Setchenov First Moscow State Medical University
Russian Federation


E. V. Moroz
I.M. Setchenov First Moscow State Medical University
Russian Federation


References

1. Snoep J.D., Hovens M.M., Eikenboom J.C. et al. Clopidogrel nonresponsiveness in patient undergoing percutaneous intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007; 154: 221-231.

2. Lee P ., Chen W., Ng W. et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005;118: 723–7.

3. Gurbel P .A., Bliden K.P ., Hayes K.M., Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardioll 2005;45:1392-6.

4. Gori A.M., Marcucci R., Migliorini A. et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52(9):734-9.

5. Sibbing D., Braun S., Morath T . et al. Platelet reactivity after clopidogrel treatment assessed with point–of–care analysis and early drug–eluting stent thrombosis. J Am Coll Cardiol 2009;53(10):849–56.

6. Collet J.P ., Silvain J., Landivier A. et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with clopidogrel before coronary Angioplasty in subjects treated long term with Dual antiplatelet therapy (RELOAD) study. Circulation 2008;118:1225–33.

7. Montalescot G., Wiviott S.D., Braunwald E. et al. for the TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723–31.

8. Cannon C.P ., Harrington R.A., James S. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283–93.

9. Price M.J., Angiolillo D.J., Teirstein P .S. et al. Platelet reactivity and cardiovascular outcomes after per-cutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011;124(10): 1132-7.

10. Marcucci R., Gori A.M., Paniccia R. et al. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 2010; 104:279-286.

11. Brar S.S., ten Berg J., Marcucci R. et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58(19):1945-54.

12. Nijjer S.S., Davies J.E., Francis D.P . Quantitative comparison of clopidogrel 600mg, prasugrel and ticagrelor , against clopidogrel 300mg on major adverse cardiovascular events and bleeding in coronary stenting: Synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. Int J Cardiol 2012. [Epub ahead of print]

13. Frelinger A.L. 3rd, Michelson A.D., Wiviott S.D. et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011;106(2):219-26.

14. Men'shikov V.V., editor . Methodology of clinical trials. A Reference Guide. Moscow: Labora; 2008. Russian (Меньшиков В.В., редактор. Методики клинических исследований. Справочное пособие. М.: Лабора; 2008).

15. Gum P .A., Kottke-Marchant K., Welsh P .A. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41(6):961-5.

16. Gurbel P .A., Bliden K.P ., Zaman K.A. et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005;111(9):1153-9.

17. The CURRENT–OASIS 7 Investigators Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. N Engl J Med 2010; 363:930-42.

18. Ferguson A.D., Dokainish H., Lakkis N. Aspirin and clopidogrel response variability: review of the published literature. Tex Heart Inst J 2008;35(3):313–20.

19. von Beckerath N., Kastrati A., Wieczorek A. et al. A double–blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007;28(15):1814–9.

20. Curzen N., Sambu N. Antiplatelet therapy in percutaneous coronary intervention: is variability of response clinically relevant? Heart 2011;97:1433-1440

21. Angiolillo D.J. Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010; 31: 17-28.


For citation:


Sulimov V.A., Moroz E.V. RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION. Rational Pharmacotherapy in Cardiology. 2012;8(1):23-30. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-1-23-30

Views: 432


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)